Progenics Pharmaceuticals Announces Presentation of Updated Safety and Tolerability Data for AZEDRA® (iobenguane I 131) at t...
November 19 2018 - 4:30PM
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), an oncology company
developing innovative medicines and imaging analysis technology for
targeting and treating cancer, today announced that safety and
tolerability data from a pooled analysis of four open-label, Phase
1 and 2 studies of AZEDRA (iobenguane I 131) in patients with
iobenguane scan positive cancers will be presented in an oral
session at the upcoming Radiological Society of North America
(RSNA) 2018 Annual Meeting, which will be held November
25-30, 2018, in Chicago, IL
Presentation details are as follows:
Date & Time: Monday,
November 26, 2018, 4:30 PM – 6:00 PM CTSession
Title: Special Interest Session: High Impact Clinical
TrialsSession Type: Oral Abstract
PresentationTitle: Safety and Tolerability of
High-Specific-Activity I-131 MIBG (AZEDRA®) in Patients with
Iobenguane Scan Positive Cancers: A Pooled Analysis Across AZEDRA
Clinical StudiesPresenter: Miguel Pampaloni, MD,
PhD, Associate Professor of Radiology and Medicine and Chief of
Nuclear Medicine in the Department of Radiology and Biomedical
Imaging at the University of California, San
Francisco.Abstract Number: SPSI26C
For important risk and use information
about AZEDRA, please see Full Prescribing
Information.
About PROGENICS
Progenics develops innovative medicines and
other technologies to target and treat cancer, including: 1)
therapeutic agents designed to treat cancer (AZEDRA®, PSMA TTC and
1095), 2) PSMA-targeted imaging agent for prostate cancer (PyL™),
and 3) imaging analysis technology (PSMA AI and aBSI). Progenics
has two commercial products, AZEDRA, for the treatment of
unresectable, locally advanced or metastatic pheochromocytoma or
paraganglioma (rare neuroendocrine tumors of neural crest origin)
who require systemic anticancer therapy; and
RELISTOR® (methylnaltrexone bromide) for opioid-induced
constipation, which is partnered with Bausch Health Companies,
Inc.
This press release contains projections and
other "forward-looking statements" regarding future events.
Statements contained in this communication that refer to Progenics'
estimated or anticipated future results or other non-historical
facts are forward-looking statements that reflect Progenics'
current perspective of existing trends and information as of the
date of this communication. Forward looking statements generally
will be accompanied by words such as "anticipate," "believe,"
"plan," "could," "should," "estimate," "expect," "forecast,"
"outlook," "guidance," "intend," "may," "might," "will,"
"possible," "potential," "predict," "project," or other similar
words, phrases or expressions. Such statements are predictions
only, and are subject to risks and uncertainties that could cause
actual events or results to differ materially. These risks and
uncertainties include, among others, market acceptance for approved
products; the risk that the commercial launch of AZEDRA may not
meet revenue and income expectations; the cost, timing and
unpredictability of results of clinical trials and other
development activities and collaborations; the unpredictability of
the duration and results of regulatory review of New Drug
Applications (NDA) and Investigational NDAs; possible product
safety or efficacy concerns, general business, financial,
regulatory and accounting matters, litigation and other risks. More
information concerning Progenics and such risks and uncertainties
is available on its website, and in its press releases and reports
it files with the U.S. Securities and Exchange Commission,
including those risk factors included in its Annual Report on Form
10-K for the annual period ended December 31, 2017, as updated in
its subsequent Quarterly Reports on Form 10-Q. Progenics is
providing the information in this press release as of its date and,
except as expressly required by law, Progenics disclaims any intent
or obligation to update or revise any forward-looking statements,
whether as a result of new information, future events or
circumstances or otherwise.
Additional information concerning Progenics and
its business may be available in press releases or other public
announcements and public filings made after this release. For more
information, please visit www.progenics.com. Information on or
accessed through our website or social media sites is not included
in the company's SEC filings.
(PGNX-F)
Contact: |
|
Melissa
DownsInvestor Relations(646) 975-2533mdowns@progenics.com |
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Mar 2024 to Apr 2024
Progenics Pharmaceuticals (NASDAQ:PGNX)
Historical Stock Chart
From Apr 2023 to Apr 2024